Breast Cancer

Survivor Erica Deligne discusses "going flat," the power of internal beauty and how fashion helps patients reclaim their autonomy.

Breast cancer survivor Erica Deligne advocates for body autonomy and challenges the medical industry’s default toward breast reconstruction.

Oncology nurse Tammy Zinn, an Extraordinary Healer finalist, expanded support through wish-granting programs, counseling and survivorship care for patients with cancer.

Dr. Erica Mayer of Dana-Farber highlights new data on chemotherapy-free HER2+ treatment, ctDNA monitoring and oral SERDs at ESMO Breast 2026.

The FDA approved Enhertu for presurgical HER2+ breast cancer treatment. Dr. Shanu Modi discusses the "win-win" for patient efficacy and safety.

A survivor shares why advocating for a mammogram past age 75 led to a crucial second diagnosis and why family history means staying vigilant for life.

New research suggests biologic aging and neighborhood-related stress may affect how aerobic exercise influences cognition after breast cancer treatment.

A moving journey through breast cancer, discovering that vulnerability is courage and a diagnosis doesn't have to define your spirit or faith.

The FDA approved Enhertu for certain patients with HER2-positive early-stage breast cancer before and after surgery based on DESTINY trial data.

My experience with cancer has affected the way I think about the health of my pets. Whereas the old me was more fatalistic, the survivor in me would go an extra mile to save a beloved creature.

ctDNA liquid biopsies detect breast cancer at molecular levels to guide personalized therapy and monitor for recurrence or progression.

Dr. Susan MacDonald breaks down the TNM staging system (Tumor, Nodes, Metastasis) to help patients understand their clinical diagnosis.

Experts urge caution with ctDNA testing in early-stage breast cancer, citing "molecular anxiety" and a lack of clear clinical data on survival outcomes.

Oncology dietitians shared smoothie and turmeric latte recipes to help patients with breast cancer manage nutrition during treatment.

Learn about the FDA approval of Veppanu, the first PROTAC for ER+/HER2- metastatic breast cancer with ESR1 mutations.

A cancer survivor reflects on the profound power of physician communication, highlighting how words can either validate hope or deepen patient pain.

A breast cancer survivor shares how faith and community prayer provided unexplainable peace and a new mission to offer hope to others in need.

Following the FDA approval of Veppanu for ESR1-mutant breast cancer, Dr. Komal Jhaveri explains this new therapy that destroys cancer receptors.

Phase 3 VIKTORIA-1 trial shows gedatolisib triplet therapy significantly extends progression-free survival for HR+/HER2- advanced breast cancer.

Learn about rare phyllodes tumors, from benign to malignant grades, including surgical options, recovery and key questions for your oncology team.

Following FDA approval, Veppanu (vepdegestrant) provides a new oral treatment option for patients with ESR1-mutated, ER+/HER2- metastatic breast cancer.

Summer, with its promise of warmth and freedom, can present unexpected challenges for breast cancer survivors navigating life after a mastectomy.

New AHN research shows high-intensity resistance training is safe and essential for breast cancer survivors to gain strength and functional mobility.

Urologist Dr. Susan MacDonald breaks down the differences between soft tissue and blood cancers while highlighting common and rare disease types.

Phase 3 trial shows Datroway significantly extended overall and progression-free survival in patients with previously untreated, advanced TNBC ineligible for immunotherapy.